Chugai Seiyaku Kabushiki Kaisha

Masahiro Nishimoto

Tsutomu Sato

Yoshikazu Nishimura

Kazumi Morikawa

Yoshitake Kanbe

Satoshi Tsuchiya

Atsushi Matsuo

Hirotaka Kashiwagi

Nobuyuki Hori

Masahide Aoki

Satoshi Tanida

Shoshin Yoshida

Hiroko Ogawa

Kyoko Oguri

Takuma Kamon

Takahiro Kawai

Hitoshi Yoshino

Yoshiyuki Furuta

MyungHwa Kim

Takuya Shiraishi

JaeChon Jo

Jaeyoung Choi

HeeAn Kwon

David Mark Wallace

Gary David Lopaschuk

Jong Min Kim

Jason Roland Dyck

Jie Fei Cheng

Thomas Arrhenius

Hiroharu Matsuoka

Sovouthy Tith

HyunSuk Lim

Takamitsu Kobayashi

Ju Su Kim

Myung Hwa Kim

Jae Chon Jo

PilSu Ho

Hyun Suk Lim

JongMin Kim

Bin Liu

Nobuo Shimma

Mi Chen

Mark E Wilson

Takashi Emura

Masahiro Sakaitani

Alex Michael Nadzan

Yujin Huang

Rossy Serafimov

Yoshihito Ohtake

Charles Stanford Harmon

Steve Joel Brown

HongIl Heo

JuSu Kim

Sang-Hak Lee

Yasuhara Kato

YoungJun Na

SungOh Ahn

KooHyeon Ahn

Kyouko Takami

HongKi Kim

SungDae Park

Marina Yamaguchi

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Provided are a compound represented by Formula (I):  or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Fused ring spiroketal derivative and use thereof as anti-diabetic drug

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is &#x2014;O&#x2014;, &#x2014;CH&#x2014;, or &#x2014;NH&#x2014;; n is an integer selected between 0 and 1; Rand Reach independently is hydrogen or Calkyl; m is an integer selected among 1-3; Q is selected among the following formulae Qto Q; Aris optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Aris optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes

The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; Rto Reach independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes

The present invention provides a compound of Formula (I): 

Spiroketal derivatives and use thereof as diabetic medicine

The present invention relates to methods of treatment of certain metabolic diseases, and to the use of compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, the invention relates to the use of compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the following formulae: (I) and (II) Wherein Y, C, R, R, R, and Rare defined herein. 

Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases

The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators

The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which

Compounds with hydroxycarbonyl-halogenoalkyl side chains

The present invention relates to a novel benzopyran or thiobenzopyran derivative represented by formula (1): pharmaceutically acceptable salt or stereoisomer thereof, in which X, R, R, R, Rand A are defined as described in the specification, and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (1) as an active component.

Benzopyran or thiobenzopyran derivatives

Growing community of inventors

Shizuoka, Japan

Masahiro Nishimoto